Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 15/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.75 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.75 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6774961 | 1.00 | CCR3 (0.75) | CCR3SLC6A4SLC6A2SLC6A3NAMPT | |
| SCHEMBL6773025 | 0.94 | CCR3 (0.74) | CCR3SLC6A4SLC6A2SLC6A3NAMPT | |
| SCHEMBL6774750 | 0.88 | CCR3 (0.68) | CCR3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6774752 | 0.88 | CCR3 (0.68) | CCR3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6780550 | 0.85 | CCR3 (1.00) | CCR3SLC6A4SLC6A2SLC6A3HTR2A | |
| SCHEMBL6780545 | 0.85 | CCR3 (1.00) | CCR3SLC6A4SLC6A2SLC6A3HTR2A | |
| SCHEMBL7656814 | 0.83 | CCR3 (1.00) | CCR3SLC6A4SLC6A2SLC6A3HTR2A | |
| SCHEMBL7656820 | 0.83 | CCR3 (1.00) | CCR3SLC6A4SLC6A2SLC6A3HTR2A | |
| SCHEMBL18840939 | 0.83 | CCR3 (1.00) | CCR3SLC6A4SLC6A2SLC6A3HTR2A | |
| SCHEMBL18840912 | 0.80 | CCR3 (1.00) | CCR3SLC6A4SLC6A2SLC6A3ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144273-A1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | WATSON PAUL S (US) | 2003-07-31 | — | — | US | claimed |
| US-6441001-B1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-27 | — | — | US | claimed |
| US-6706735-B2 | NITROGEN COMPOUNDS SUCH AS N-(3-(4-BENZYL-2-PIPERIDINYL)PROPYL )-N'-(3-CYANOPHENYL)UREA, USED AS CHEMOTACTIC CYTOKINE CONTROLLERS ADMINISTERED FOR PROPHYLAXIS OF ASTHMA, ALLERGIES AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-16 | — | — | US | disclosed |
| US-20030144273-A1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | WATSON PAUL S (US) | 2003-07-31 | — | — | US | disclosed |
| US-6441001-B1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-27 | — | — | US | disclosed |
| EP-1140833-A1 | 2-SUBSTITUTED-4-NITROGEN HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035876-A1 | 2-SUBSTITUTED-4-NITROGEN HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144273-A1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | CCR3, CCR1, CCR4 | CCR3 1/4885SLC6A4 2663/4885SLC6A2 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.